We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
The new dual agonist Survodutide showed 13% weight reduction in patients with obesity without diabetes. Learn about the mechanism of action, side effects, and prospects of the drug.
